Hypoxia Inhibits Osteogenesis in Human Mesenchymal Stem Cells through Direct Regulation of RUNX2 by TWIST

Der-Chih Yang1,5, Muh-Hwa Yang1,7, Chih-Chien Tsai2,5,9, Tung-Fu Huang3,6,7, Yau-Hung Chen4*, Shih-Chieh Hung1,2,5,6*

1 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 2 Pharmacology, National Yang-Ming University, Taipei, Taiwan, 3 Department of Surgery, National Yang-Ming University, Taipei, Taiwan, 4 Department of Chemistry, Tamkang University, Taipei, Taiwan, 5 Department of Medical Research and Education, Veterans General Hospital-Taipei, Taipei, Taiwan, 6 Orthopaedics and Traumatology, Veterans General Hospital-Taipei, Taipei, Taiwan, 7 Hematology-Oncology, Veterans General Hospital-Taipei, Taipei, Taiwan

Abstract

Background: Bone loss induced by hypoxia is associated with various pathophysiological conditions, however, little is known about the effects of hypoxia and related signaling pathways on osteoblast differentiation and bone formation. Because bone marrow-derived mesenchymal stem cells (MSCs) survive under hypoxic conditions and readily differentiate into osteoblasts by standard induction protocols, they are a good in vitro model to study the effects of hypoxia on osteoblast differentiation.

Methodology/Principle Findings: Using human MSCs, we discovered TWIST, a downstream target of HIF-1α, was induced under hypoxia and acted as a transcription repressor of RUNX2 through binding to the E-box located on the promoter of type 1 RUNX2. Suppression of type 1 RUNX2 by TWIST under hypoxia further inhibited the expression of BMP2, type 2 RUNX2 and downstream targets of RUNX2 in MSCs.

Conclusions/Significance: Our findings point to the important role of hypoxia-mediated signalling in osteogenic differentiation in MSCs through direct regulation of RUNX2 by TWIST, and provide a method for modifying MSC osteogenesis upon application of these cells in fracture healing and bone reconstruction.

Citation: Yang D-C, Yang M-H, Tsai C-C, Huang T-F, Chen Y-H, et al. (2011) Hypoxia Inhibits Osteogenesis in Human Mesenchymal Stem Cells through Direct Regulation of RUNX2 by TWIST. PLoS ONE 6(9): e23965. doi:10.1371/journal.pone.0023965

Editor: David S. Milstone, Brigham and Women’s Hospital, United States of America

Received December 18, 2010; Accepted August 2, 2011; Published September 9, 2011

Copyright: © 2011 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by grants from the National Science Council (97-3111-B-010-001, 97-2313-B-032-001-MF3, 98-3111-B-010-001-, 98-2628-B-010-001-MF3), the Taipei Veterans General Hospital (V98E1-009, V98E1-002, V99E1-011), and National Yang-Ming University, Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing Interests: The authors have declared that no competing interests exist.

E-mail: hungsc@vghtpe.gov.tw (S-Ch); yauhung@mail.ncku.edu.tw (Y-HC)

These authors contributed equally to this work.

Introduction

Bone loss induced by hypoxia is associated with various pathophysiological conditions such as ischemia [1], vascular diseases [2,3], and osteolytic bone metastases [4]. Although, hypoxia was reported to control osteoclast size and numbers [5], however, little is known about the effects of hypoxia on osteoblast differentiation and bone formation.

RUNX2 (also known as CBFA1) is a master regulator of skeletogenesis and its expression is required for the expression of several downstream genes that are important for osteoblast differentiation and maturation [6,7]. The major isoforms of RUNX2 involved in osteogenesis are type1 (T1) and type2 (T2) RUNX2. T1 RUNX2 is regulated by a proximal promoter P2 and the translation begins from the exon2 amino acid sequences (MRIPVD); whereas T2 RUNX2 is regulated by a distal promoter P1 and translation begins from the exon1 amino acid sequences (MASNSL). T1 RUNX2, chiefly expresses in early precursors of osteoblasts and chondrocytes [8], and is upregulated by growth factors such as fibroblast growth factor 2 (FGF2) to stimulate the production of bone morphogenetic protein2 (BMP2). This then enhances the transcription of T2 RUNX2 to stimulate osteoblast differentiation and maturation [9].

The transcriptional response to hypoxia is mediated by the hypoxia-inducible transcription factor (HIF-1), a heterodimer consisting of the constitutively expressed aryl hydrocarbon receptor nuclear translocator (ARNT) and the hypoxic response factor HIF-1α. HIF-1α is regulated by the cellular O2 concentration and determines the transcriptional activity of HIF-1 [10]. Twist, a basic helix-loop-helix (bHLH) transcription factor, has been known to promote tumor metastasis by inducing epithelial-mesenchymal transition (EMT) [11]. Recently, Twist is known as one of the downstream targets of HIF-1α and the HIF-Twist pathway is involved in hypoxia-induced increase of metastasis in head and neck cancer [12] and hypoxia-mediated inhibition of replicative senescence and loss of stemness occurred upon expansion of adult stem cells [13].

Human multipotent stromal cells or mesenchymal stem cells (MSCs), capable of self renewal and differentiating into various mesenchymal tissues [14], have emerged as a promising tool for...
clinal applications in, for example, cell-based therapy for osteogenesis imperfecta [15] and tissue engineering in cartilage and bone [16]. MSCs reside in bone marrow and are easily isolated by plastic-adherence. They are the in vivo precursors of osteoblasts and are readily induced to undergo osteoblastic differentiation by standard induction protocols. Therefore they are a good non-cancerous model to study osteogenic differentiation and bone formation [12,17].

Because MSCs isolated from bone marrow, which is hypoxic in nature (1–7% O2), survive under hypoxia [18], we used MSCs as the cell model to study the underlying mechanism involved in hypoxia-mediated inhibition of osteogenesis. Since the TWIST levels are increased in MSCs cultured under hypoxic conditions, remain high in freshly purified MSCs, and are downregulated following ex vivo expansion, we specifically focused on the role of TWIST in modulating of osteogenesis of MSCs under hypoxic conditions [19,20]. Our findings provide evidence that hypoxia inhibits MSC osteogenesis through direct downregulation of RUNX2 by TWIST.

Results

Hypoxia inhibits osteogenic differentiation by MSCs

To understand the effects of hypoxia on osteogenic differentiation, we induced bone marrow MSCs from three individual donors in osteogenic induction medium (OIM) under normoxia (21% O2) and hypoxia (1% O2). The expression of RUNX2 was detected at 3 days of differentiation and the expression level was greater under normoxia than hypoxia both as mRNA (Figure 1A) and protein (Figure 1B) in all three MSCs. The iron chelator desferrioxamine (DFX) has been shown to mimic hypoxic state in regulating several hypoxia-responsive genes [21]. Similarly, decreased RUNX2 expression was also noted in cells treated with DFX (Figure 1C, D). Further both hypoxia and DFX induced a decrease in the expression of RUNX2 downstream target genes, such as alkaline phosphatase (AP), bone sialoprotein (BSP), collagen type 1 alpha 1 (COL1A1), osteopontin (OP) and osteocalcin (OC), (Figure S1). Induction under hypoxia also had an inhibitory effect on the functional mineralization of MSCs both at 14 and 21 days of osteogenic differentiation (Figure 1E).

Hypoxia inhibits expression of type1 RUNX2 and its downstream targets

Similar to induction by FGF2 [9], MSCs induced in OIM that contains dexamethasone, increased in T1 RUNX2 and BMP2 expression as early as 12 h after induction, followed by a delayed increase in the expression of T2 RUNX2 at 24 h (Figure 2A). Interestingly, noggin, a BMP2 antagonist, blocked the increase in T2 RUNX2 expression [22] but not T1 RUNX2 (Figure 2B), suggesting that T1 RUNX2 upregulated T2 RUNX2 expression occurred through BMP2. To explore the key molecule that hypoxia or DFX targeted to regulate osteogenesis, we first found both the expression of T1 and T2 RUNX2 were downregulated at 3 days under hypoxia (Figure 2C). When examining the early effect of hypoxia, which could be achieved with DFX treatment, we found T1 RUNX2 and BMP2 were downregulated as early as 12 h, while T2 RUNX2, OC and OP were only downregulated at 24 h after treatment (Figure 2D, E). Further, the presence of BMP2 inhibited the DFX-mediated downregulation of T2 RUNX2, OC and OP but not T1 RUNX2 (Figure 2F).

Hypoxia downregulates type1 RUNX2 through the HIF-1α-TWIST pathway

To examine the molecular mechanism that hypoxia mediated to inhibit osteogenesis, we first demonstrated both HIF-1α and TWIST were upregulated under hypoxia and DFX treatment (hypoxia mimic condition) in MSCs from three individuals (Figure 3A, B). To assess the role of TWIST in regulating differentiation into osteoblasts, MSCs were transfected with overexpression construct, pFLAG-TWIST (control: pFLAG-CMV1), or shRNA construct, pSuper-TWIST-si (control: pSuper-Scramble) in OIM both without and with 100 µM DFX (Hyp) for 2 days. Interestingly, overexpression of TWIST suppressed the expression of T1, T2 RUNX2, total RUNX2 and OC under normoxia (Figure 3C), while a small effect was noted under hypoxia (Figure S2A). In contrast, knockdown of TWIST stimulated the expression of these genes under hypoxia (Figure 3D), while a small effect was noted under normoxia (Figure S2B). These results suggested the HIF-1α-TWIST pathway regulates osteogenesis by MSCs.

TWIST suppresses type 1 RUNX2 promoter activity

To demonstrate whether RUNX2 was directly regulated by TWIST during osteogenesis, analysis of the human RUNX2 P2 (for T1 RUNX2) and P1 (for T2 RUNX2) promoter activity was performed using luciferase reporter constructs in a MSC cell line. We first revealed the upregulation of P2 (Figure 4A, B) but not P1 promoter activity (Figure S3A) upon induction in OIM, while the P1 promoter activity, consistent with a previous report [22], was stimulated by overexpression of β-catenin [23] (Figure S3A). Interestingly, DFX treatment or overexpression of TWIST abrogated the upregulation of P2 promoter in a dose dependent manner (Figure 4B). Similarly, DFX treatment or hypoxia or overexpression of TWIST in 293T cells also downregulated the promoter activity of P2 in a dose-dependent manner (Figure 4C). However, DFX treatment or overexpression of TWIST did not inhibit β-catenin-induced increase in the P1 promoter activity (Figure S3A). These data suggest TWIST directly inhibited P2 promoter activity in MSCs undergoing osteogenic differentiation.

TWIST directly binds to RUNX2 P2 promoter

TWIST is reported to bind to the E-box motifs to regulate transcription [24]. To identify the minimum promoter region required for induction by TWIST, a series of 5′ P2 promoter deletion constructs were generated. Deletions of the −1502 to −1232, but not other regions, significantly inhibited the suppressive effect of TWIST on the promoter activity (Figure S3B). These findings suggest the existence of a TWIST-responsive sequence in the −1502 to −1232 promoter region. To further find where TWIST binds to pGL3-RUNX2 P2 (WT) promoter, site-directed mutagenesis of the putative E-box in the P2 promoter prevented suppression under TWIST was examined. The pGL3-RUNX2 P2 (E1M) (distal first E-box mutation) and pGL3-RUNX2 P2 (E1E5M) (first and fifth E-boxes double mutations) of the P2 promoters significantly inhibited the TWIST-mediated suppression of the promoter activity in a same degree in 293T, while pGL3-RUNX2 P2 (E5M) did not inhibit any change on TWIST effect (Figure 4D), suggesting the E1-box in the P2 promoter was the binding site for TWIST. To determine the E1-box binding domain in TWIST, a construct with truncated 316–492 a.a basic helix-loop-helix (bHLH), pFLAG-bTLWIST, was transfected to 293T, truncation of the bHLH domain abrogated the inhibition of P2 promoter activity by TWIST (Figure 4E).

Electrophoretic mobility shift assays (EMSAs) using an oligonucleotide containing the E1-box sequence from RUNX2 P2 promoter incubated with nuclear extracts of TWIST-overexpressing 293T cells demonstrated the direct binding of TWIST to the wild-type probe (TWIST E1-box sequences (TEB)) (Figure 4F, lane 2, 8 and 14 v.s. no nuclear extract controls at Figure 4A, lane 1, 7 and 13). Competition by unlabelled wild type probe abolished
the binding activity (Figure 4F, lane 3–4, 9–12), but the mutated probe did not show the same effect (Figure 4F, lane 5 and 6). Addition of anti-TWIST antibodies, rather than isotype antibodies, into TWIST-overexpressing nuclear extracts showed a supershifted band in gel electrophoresis (Figure 4F, lane 15). To investigate whether TWIST is directly associated with the RUNX2 P2 promoter via binding to E1-box, we performed chromatin immunoprecipitation (ChIP). PCR amplification (Figure 4G, left panel) and real-time PCR (Figure 4G, right panel) showed that the fragments containing the E1-box (180 bp) were immunoprecipitated with TWIST antibody in a MSC cell line and 293T after transfection of pFLAG-TWIST. However, an internal control of RUNX2 promoter (−943 to −878) that does not contain the binding site (Figure S4A) and the unrelated promoters of GAPDH (Figure S4B), BCL-2 (Figure S4C) and NKG2A (Figure S4D) were not immunoprecipitated with TWIST antibody. These data taken together suggest TWIST downregulated P2 promoter activity by direct binding through the bHLH domain to the E1-box in the P2 promoter.

Discussion

Oxygen (O2) is a substrate for energy production in the cell and is a rapid regulator of cellular metabolism. Recent studies have

Figure 1. Hypoxia inhibits the expression of RUNX2 and the mineralization capacity of MSCs and zebrafish. MSCs form three individuals (D1, D2, and D3) were induced in OIM under normoxia (Nor) or hypoxia (Hyp) (A, B) or treated with indicated concentration of DFX for 3 days (C, D) (n = 3). Cells were analyzed by quantitative RT-PCR (A, C) and Western blotting (B, D). Results are shown as the mean ± SD values. Significance was determined by Student’s t-test. (* p<0.05 and ** p<0.01 versus Nor or without DFX). E, MSCs without (CTR) or with induction in OIM under normoxia or hypoxia for 14 or 21 days were stained by Alizarin Red S (ARS) and quantification of staining was performed by optic density (O.D.) measurement at O.D.550 nm (n = 3).

doi:10.1371/journal.pone.0023965.g001
also implicated O2 and its signal transduction pathways in controlling cell proliferation, fate, and morphogenesis during the development of many tissues [25], including the skeletal system [26,27]. Hypoxia has recently been reported by us and others to inhibit osteogenesis in MSCs and osteoblast [18,28,29], however the detailed mechanism underlying the inhibition effects of

Figure 2. Expression of Type1 and Type2 RUNX2 in MSCs induced for osteogenic differentiation. Quantitative RT-PCR for mRNA levels of indicated genes. A, MSCs were induced in OIM for indicated time period (n = 3). B, MSCs were induced in OIM without or with noggin treatment for 24 h (n = 3). C, MSCs were induced in OIM under normoxia (Nor) or hypoxia (Hyp) for 3 day (n = 3). D, E, MSCs were induced in OIM or with indicated concentration of DFX for indicated time period (n = 3). F, MSCs were induced in OIM in the presence of DFX without or with rhBMP2 for 24 h (n = 3). Results are shown as the relative expression to GAPDH (mean ± SD), and significance was determined by Student’s t-test. (* p<0.05 and ** p<0.01 versus black bar). doi:10.1371/journal.pone.0023965.g002
hypoxia on osteogenesis is unknown. In the current study, we discovered TWIST, a downstream target of HIF-1α, acts as a transcription repressor of RUNX2 through binding to the E-box located on the promoter of T1 RUNX2, leading to the suppression of T1 RUNX2, followed by suppression of BMP2, T2 RUNX2 and downstream targets of RUNX2 in MSCs.

Previously, T2 RUNX2 was considered important for osteogenesis. Its expression is induced upon stimulation with BMP2 or...
Figure 4. TWIST inhibits Type 1 RUNX2 transcription via binding to its promoter. A, Genomic organization of the region flanking the promoter region of human RUNX2 P2 (upper panel) and the schematic representation of the pGL3-RUNX2 P2 reporter construct. Transcription start site, TSS. B, C) Reporter assays showing, in a MSC cell line (B) or 293T (C), DFX, TWIST and exposure to hypoxia repress the RUNX2 P2 promoter activity in a dose dependent manner (n = 3). β-galactosidase was used as a control of transfection efficiency. D, Mutational analysis of E1-box and E5-box sites in the RUNX2 P2 promoter in 293T cells. Reporter constructs containing wild-type RUNX2 P2 (WT), E1-box (E1M) or E5-box (E5M) mutations, or double mutations (E1E5M) were generated and used to analyze the importance of these sites in mediating repression by TWIST (n = 3). E,
TWIST increased and decreased the expression of RUNX2 both 
[24]. The current data found overexpression and knockdown of 
expression was not affected in mice carrying Twist heterozygosity 
through a Twist box in the carboxy-terminus, while Runx2 
gene activation by Runx2 via the interaction with Runt domain 
Thus, the effects of HIF pathways on 
in vivo 
pathway and inhibited the 
formation of the flat bones of the skull [32]. In the current study, 
levels in osteoblasts in the calvarial bones did not influence the 
osteoarthritis in mice [31]. However, manipulation of HIF-1 
mutants both during skeletal development [27] and bone repairing 
in osteoblasts had the reverse skeletal phenotype of that of the Vhl 
demonstrated the induction of 
**-catenin-induced increase in 
activity in MSCs undergoing osteogenic differentiation. Interest-
ingly, there are four E-boxes in the PI promoter. Therefore it would 
be interesting to clarify why TWIST did not inhibit the PI promoter 
activity. Although *T1 RUNX2* is constantly expressed in various cells 
including osteoblasts, its expression is seldom, if ever, emphasized in 
estogenes and bone formation [30]. The current data first 
demonstrated the induction of *T1 RUNX2* in MSCs undergoing 
estogenesis, and found a putative TWIST binding site, E1-box, in the 
RUNX2 P2 promoter. To our knowledge, it has not been 
demonstrated before that *T1 RUNX2* is an important target for 
controlling osteogenesis by hypoxia or HIF-1**-TWIST, an 
important environment or signaling occurred during a lot of 
pathophysiologica conditions associated with normal development 
and regeneration, or acquired and genetic diseases. Therefore, 
signaling pathways or molecules that control the transcription of *T1 
RUNX2* may be modified to control MSC osteogenesis upon 
application of these cells in treating bone diseases especially 
associated with ischemia and hypoxic conditions. 

The roles of HIF proteins and downstream signaling pathways 
in skeletal development have recently been studied. The HIF-1 
pathway has been identified as a key component in the coupling of 
angiogenesis and osteogenesis during bone development and 
regeneration [26,27]. Mice overexpressing Hif-1** in osteoblasts 
through selective deletion of the von Hippel-Lindau gene (Vhl) 
expressed high levels of Vegf and developed extremely dense, 
heavily vascularized long bones. By contrast, mice lacking Hif-1** in 
obesteoblasts had the reverse skeletal phenotype of that of the Vhl 
mutants both during skeletal development [27] and bone repairing 
process [26]. Moreover, HIF-2**, independently of oxygen-
dependent hydroxylation, has recently been reported essential 
for endochondral ossification of cultured chondrocytes and 
embryonic skeletal growth, and important for development of 
ostearthritus in mice [31]. However, manipulation of HIF-1** levels in 
obesteoblasts in the calvarial bones did not influence the formation of 
the flat bones of the skull [32]. In the current study, 
we found HIF-1** activated TWIST, which in turn repressed 
transcription of RUNX2 and inhibited osteogenic differentiation 
in MSCs. Consistent with the *in vitro* study, exposure of zebrafish to 
hypoxia or hypoxia-mimicking agent also induced the hif-twist 
pathway and inhibited the *in vivo* bone formation [2nd paper]. 
Thus, the effects of HIF pathways on *in vitro* osteogenesis and *in vivo* 
bone formation are context and situation-specific. 

Bialek et al. demonstrated Twist inhibited DNA binding and 
gene activation by Runx2 via the interaction with Runx domain 
through a Twist box in the carboxy-terminus, while Runx2 
expression was not affected in mice carrying Twist heterozygosity 
[24]. The current data found overexpression and knockdown of 
TWIST increased and decreased the expression of RUNX2 both 
as mRNA and protein, respectively. The discrepancy between 
these two studies may be due to the suppression of Twist 
expression by Twist heterozygosity in mice is not sufficient to 
downregulate Runx2. The negative role of TWIST in regulating 
estogenesis has also been implicated in phenotypic abnormalities 
seen in human disorders with TWIST mutation, such as Saethre–
Chotzen syndrome [33,34], an autosomal dominant disorder with 
characteristic abnormalities in craniosynostoses resulting from 
premature closure of cranial sutures, short stature, and develop-
mental limb deformities (syndactyly and polydactyly). Future 
exploration of the TWIST signaling pathways may help in 
developing strategies to control osteogenesis and skeleton develop-
ment through RUNX2 suppressions. In conclusion, these data 
suggest the important roles of TWIST in regulating RUNX2 
expression and controlling MSC osteogenesis. Further exploration 
of the molecules or signaling pathways that are involved in 
TWIST regulation may provide new strategies for modifying these 
cells in treating fracture healing and bone reconstruction. 

**Methods**

**Cell culture and oxygen deprivation**

The Primary MSCs were gifted by Dr. D.P. Prockop, isolated as 
previously described [35] and grown in CCM [MEM (Gibco) with 
16.6% FBS, 100 U/ml penicillin, and 10 µg/ml streptomycin] at 
37°C under 5% CO2 atmosphere. The medium was changed 
twice a week and subcultured at 1:5 at subconfluence. For hypoxic 
conditions, cells were cultured in a gas mixture composed of 94% 
N2, 5% CO2, and 1% O2 or treated in medium containing 30 or 
100 mM of DFX that mimics the hypoxic conditions by inhibiting 
the hydroxylation of a prolyl residue that is essential for the 
ubiquitination of HIF-1**.

**Induction and histochemical studies**

For osteogenic differentiation, cells were reseeded at 10^4 cells/ 
cm^2 and induced in osteogenic induction medium (OIM; αMEM 
supplemented with 16.6% BFs, 30 µg/ml ascorbate-2-phosphate 
(Nacalai, Kyoto, Japan), 10^{-8} M dexamethasone (Sigma) and 
10 mM β-glycerophosphate (Sigma)] under normoxic and hypoxic 
conditions or treated with DFX. After induction in OIM, cells 
were fixed and stained with Alizarin Red S (Sigma) for 30 min to 
show osteogenic differentiation. Following wash five times with 
PBS, stained cultures were photographed and quantification of 
calcium deposition was made by extracting Alizarin Red S staining 
with 10% cetylpyridinium chloride and measuring the O.D. of the 
extract at 550 nm using an ELISA reader (Spectra MAX 250; 
Molecular Devices, Sunnyvale, CA).

**Plasmid constructions**

The pFLAG-CMV1, pFLAG-TWIST, pSuper-scramble-si and 
pSuper-TWIST-si plasmids were gifts from Muh-Hwa Yang 
(University of National Yang-Ming University) [16]. The
RNA extraction and quantitative RT-PCR

Total RNA was prepared by using the Trizol reagent (Invitrogen) according to the manufacturer’s specifications. First strand cDNA was synthesized using Superscript III (Invitrogen) according to the manufacturer’s specifications. The protocol of quantitative RT-PCR was performed using cDNA as the template in a 20-μl reaction mixture containing FastStart SYBR Green Master (Roche Applied Science) and a specific primer pair of each cDNA according to the published sequences:

Human GAPDH F: CTCGTGCTCCTCCTGTTGCA
Human GAPDH R: ACGACGCAAATCGTGTTA CTC
Human ALK-P F: CGCAAAAGGTCC TCCCTTG
Human ALK-P R: CTTGGAAGTCTTGTTGACGAT
Human BMP2 F: TCCACACATGAAGAATCTTGGCA
Human BMP2 R: CCTGAAAGCTCTTGAGGTTGAGTT
Human BSP F: AACACTACACCCACACGAC
Human BSP R: AGGTCCCCGCTGCTACTTTT
Human COL1A1 F: GACAGTCCTAGTTGGTGAGAA
Human COL1A1 R: CTGGTTCCACGCTGTTTCTCT
Human OC F: GACGTGTCGAGTGTGCTGCTG

pSG5HA β-catenin and pRC/CMV-LacZ plasmids were gifts from Fung-Fang Wang (University of National Yang-Ming University) [12,23]. The human RUNX2 P1 promoter (−767→+31) and P2 promoter (−1502→+12) were constructed by PCR amplification of the 293T DNA using the primer pairs: pGL3-RUNX2 P1 F: 5′-GTTGACGCAAATTTTCTGATT-3′ and pGL3-RUNX2 P1 R: 5′-TGGTTCACTGCAAGGTCTTT-3′; pGL3-RUNX2 P2 F: 5′-GTTGACGCAA GAGATTTTTTATGGCATT-3′ and pGL3-RUNX2 P2 R: 5′-GGAGCTCCCCCTAGATAAACGAGAAAC-3′. Each fragment of the pGL3-RUNX2 P1 (799 bp) or pGL3-RUNX2 P2 (1515 bp) promoter was subcloned into the pGL3 vector (Promega). A series of 5′ promoter deletion constructs (−1232→+12, −1032→+12, −852→+12, −687→+12) were generated by PCR and cloned into the KpnI-SacI sites of the pGL3 basic vector. The primer pairs used included −1232 F:5′-GGTACC TATTTGGGAA CATGGAATT-3′; −1032 F:5′-GGTACC AGGAAGACA CATGGAATT-3′; −852 F:5′-TT GGTACC TTAGCTTCA CGGTTAAA-3′; −687 F:5′-GGTACC GACACAGA CATGGAATT-3′; +12 R:5′-GAGCTT CCTCCTAGATAAACGAGAAAC-3′; +12 R:5′-GAGCTT CCTCCTAGATAAACGAGAAAC-3′. Underlined nucleotides indicate restriction enzyme sites. The pGL3-RUNX2 P2 E1-box and E5-box mutations were generated from pGL3-RUNX2 P2 (WT) using Gene Tailor™ Site-Directed Mutagenesis System (Invitrogen) with the following primer pairs: E1WT:5′-AGAAATCTACTGTTAATATTGCAATTGTGGAATGGCAGGAAAC-3′ and 5′-GCATATTACA GTAGATTCT TAAACGTGTG-3′; E1M: 5′-AGAAATCTACTGTTAATATTGCAATTGTGGAATGGCAGGAAAC-3′ and 5′-GCATATTACA GTAGATTCT TAAACGTGTG-3′.

Protein extraction, western blot analysis

The cells were rinsed with PBS and lysed in 0.2 ml of protein extraction reagent (M-PER, Pierce, Rockford, Illinois) plus protease inhibitor cocktail (HaltTM, Pierce) for 5 min on ice. Protein concentrations were determined using the BCA assay (Pierce). After being heated for 5 min at 95°C in a sample buffer, aliquots of the cell lysates were run on a 10% SDS polyacrylamide gel. Proteins were transferred to PVDF membrane filters. The filter was blocked for 1 h with TBS containing 5% nonfat dry milk and 0.05% Tween 20 and then incubated overnight at 4°C with the primary antibodies. The filter was washed 3 times for 10 min each with TBS containing 0.05% Tween 20. Bound primary antibodies were detected by incubating for 1 h with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (BD PharMingen, San Diego, CA). The filter was washed and developed using a chemiluminescence assay (Perkin Elmer Life Science, Inc., Boston, MA). Densitometric analysis was carried out using Image Master 2D Elite software (Amersham Biosciences). Anti human HIF-1α (H-206, sc-10790), TWIST (H-81, sc-15393), RUNX2 (G-19, sc-8566) and ACTIN (I-19, sc-1616) antibodies were purchased from Santa Cruz Biotechnology.

Transfections

Transfections were performed by electroporation using the Nucleofector system (Ammax Biosystems, Koln, Germany). In brief, 4×10^5 cells were resuspended in 80 μl Human MSC Nucleofector solution (Ammax Biosystems) at room temperature followed by addition of 20 μl of Human MSC Nucleofector solution containing 4 μg of DNA. The transfection was carried out under the program C-17 of the Nucleofector device, as recommended by the manufacturer. The transfected cells were then suspended in an appropriate volume of 20% FBS supplemented DMEM-LG medium and seeded for further culture. After 24 h of incubation, the medium was replaced by OIM and cells were cultured for another 2 days without or with DFX. The efficiency of transfection was evaluated by the expression of EGFP in cells transfected with pMaxGFP vector was more than 50%.

Transient transfection and luciferase assays

The reporter constructs were co-transfected into human embryonic kidney cancer cells, 293T (ATCC-CRL-11268, Manassas, VA) or immortalized MSC line with different expression vectors and internal control plasmids using Lipofectamine 2000 reagent (Invitrogen) under normoxic, hypoxic or hypoxia-mimicking conditions. At 48 h post transfection, enzyme activity was measured using the Dual-Luciferase Reporter Assay (Promega).
Electrophoretic mobility shift assay (EMSA)

Nuclear extracts were obtained from 293T cells transfected with pFLAG-TWIST. The specific activity of the [γ−32P]-labeled probes used in the assays was adjusted to 10^5 CPM/1.25 pmol DNA. The probe was incubated at 25°C for 30 min with 5 μg of nuclear extract in a buffer consisting of 10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM dithiothreitol, 10% glycerol, 1 μg poly dI/dC, bromophenol blue/50% glycerol in a total volume of 20 μl. Samples were loaded on 5% polyacrylamide gels and run at 150 V for 2 h in 1× TBE buffer. The gels were dried and exposed to x-ray film. All unlabeled competitor oligonucleotides were added before incubation with labeled oligonucleotides. For supershift assay, anti-human TWIST polyclonal antibody (1 μg (Abcam, ab50581) was added at 4°C for 1 day before the addition of labeled oligonucleotides. Densitometric analysis of the DNA–protein complexes was performed on the captured images using the typhoon 9600 and ImageMaster VDS software (Amersham Biosciences).

Chromatin immunoprecipitation assay (ChIP)

To demonstrate the binding of TWIST protein to the E1-box of RUNX2 P2 promoter, the ChIP assay was performed with a commercial kit (Upstate Biotechnology; Lake Placid, NY; www.upstatebiotech.com) using the manufacturer’s protocol with minor adjustments. The MSCs and 293T transfected with pFLAG-TWIST were grown to confluence, and formaldehyde was added directly to the culture medium at a final concentration of 1% followed by incubation for 20 min at 37°C. The cells were washed at 4°C in PBS, lysed on ice for 10 min in lysis buffer [10 mM Tris HCl, pH 8.0, 1% SDS] containing phosphatase and protease inhibitors, and incubated overnight (4°C) with anti-TWIST antibody. The subsequent steps were performed as described previously.

Supporting Information

Figure S1 Hypoxia inhibits the expression of RUNX2 downstream genes in MSCs induced for osteogenic differentiation. MSCs were induced in OIM under normoxia (Nor) or hypoxia (Hyp) for 3 days. Cells were analyzed by quantitative RT-PCR for downstream genes of RUNX2, such as alkaline phosphatase (ALK-P), bone sialoprotein (BSP), collagen type I alpha 1 (COL1A1), osteopontin (OP), and osteocalcin (OC) (n = 3). Results are shown as the relative expression to GAPDH (mean ± SD), and significance was determined by Student’s t-test. * p<0.05 and ** p<0.01 versus Nor or without DFX.

Figure S2 TWIST inhibits RUNX2 expression in MSCs undergoing osteoblast differentiation. A. MSCs were transfected with control pFLAG-CMV1 or pFLAG-TWIST vector followed by induction in OIM in the presence of 100 μM DFX (Hyp) for 2 days (n = 3). B. MSCs were transfected with control pSuper-Scramble or pSuper-TWIST-si vector followed by induction in OIM without DFX treatment (Nor) for 2 days (n = 3). Cells were assessed by Western blotting and quantitative RT-PCR. Results are shown as the mean ± SD values, and significance was determined by Student’s t-test. * p<0.05 and ** p<0.01 versus control vector.

Figure S3 Treatment with DFX and overexpression with TWIST induce no changes in Type 2 RUNX2 transcription. A. Genomic organization of the region flanking the promoter region of human RUNX2 P1 (upper panel) and the schematic representation of the pGL3-RUNX2 P1 reporter construct. Transcription start site, TSS. Reporter assays showing, in a MSC cell line, β-catenin but not osteogenic differentiation enhances the RUNX2 P1 promoter activity. Treatment with DFX and overexpression with TWIST do not repress the RUNX2 P1 promoter activity (n = 3). B. Deletion analysis of various regions in the RUNX2 P2 promoter. Reporter constructs containing wild-type RUNX2 P2 (−1302), with deletion of −1502 to −1232 (−1232), −1232 to −1032 (−1032), −1032 to −852 (−852) or −852 to −687 (−687) were generated and used to analyze the importance of these regions in mediating the repression of RUNX2 P2 promoter activity by TWIST in 293T cells (n = 3).

Figure S4 Unrelated fragments were used as internal control in ChIP analysis. ChIP analysis of MSCs after transfection with pFLAG-TWIST. The chromatin was incubated with anti-TWIST antibody. The internal control of T1RUNX2 promoter (−943 to −878) does not contain the binding site (Figure S4A) and three unrelated promoters, GAPDH (Figure S4B), BCL-2 (Figure S4C) and NGK2A (Figure S4D) were amplified by PCR (upper panel) and quantified with quantitative RT-PCR (lower panel). Input, 2% of total input lysate. Results are shown as the mean ± SD values.

Acknowledgments

This work was assisted in part by the Division of Experimental Surgery of the Department of Surgery, Taipei Veterans General Hospital.
Author Contributions
Conceived and designed the experiments: D-CY T-FH Y-HC SCH. Performed the experiments: D-CY M-HY C-CT T-FH Y-HC SCH. Analyzed the data: D-CY M-HY C-CT T-FH Y-HC SCH. Contributed reagents/materials/analysis tools: Y-HC SCH. Wrote the paper: D-CY Y-HC SCH.

References
1. Vogt MT, Cauley JA, Kuller LH, Nevitt MC (1997) Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 12: 293–299.
2. Alajajian K, Juby A, Hanley D, Tynagh W, Slater A (2003) Role of vascular factors in osteoporosis. J Gerontol A Biol Sci Med Sci 58: 362–366.
3. Larochelle M, Moulind L, Leger P, Lefebvre D, Mazieres B, et al. (2003) Bone mineral decrease in the log with unilateral chronic occlusive arterial disease. Clin Exp Rheumatol 21: 103–106.
4. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteoblastic bone metastases of breast cancer. Cancer Res 67: 4157–4163.
5. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1: a master regulator of skeletal morphogenesis, plays an essential role in tumor metastasis. Cell 90: 588–594.
6. Yard P, Zhang R, Geoffroy V, Rittger AL, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 755–764.
7. Sudhakar S, Kata MS, Elango N (2001) Analysis of type-I and type-II RUNX2 protein expression in osteoblasts. Biochem Biophys Res Commun 286: 74–79.
8. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW, 2nd, et al. (1997) Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2)-transgenic mice. Mol Biol Cell 6: 1861–1873.
9. Senenza GL (1998) Hypoxia-inducible factor-1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8: 588–594.
10. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295–305.
11. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, et al. (2011) Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117: 459–469.
12. Goldberg MA, Dunnig SP, Bunn HF (1988) Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242: 1412–1415.
13. Gaur T, Lengauer CJ, Hovhannisyan H, Bhat RA, Bodine PV, et al. (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280: 33132–33140.
14. Haich PC, Chang JC, Sun WT, Haih SC, Wang MC, et al. (2007) p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates beta-catenin pathway. Oncogene 26: 4928–4940.
15. Bialek P, Kern B, Yang X, Schroek M, Socie D, et al. (2004) A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423–435.
16. Webster WS, Ahela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81: 215–228.
17. Yang C, Gilbert SR, Wang Y, Cao X, Chen X, et al. (2008) Activation of the hypoxia-inducible factor-alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A 105: 698–699.
18. Wang Y, Yuan C, Deng L, Liu X, Cao X, et al. (2007) The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117: 1610–1626.
19. Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, et al. (2007) Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 6: 745–757.
20. Utting JC, Robins SF, Brandao-Burch A, Orris IR, Behar J, et al. (2006) Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 312: 1693–1702.
21. Xiao ZS, Thomas R, Hinson TK, Quarles LD (1990) Genomic structure and isoterm expression of the mouse, rat and human Cbfa1/Osf2 transcription factor. Gene 102: 187–197.
22. Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, et al. (2005) Transcriptional regulation of endothondial ossification by HIF-zalpaha during skeletal growth and osteoarthritis development. Nat Med 16: 678–686.
23. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295–305.
24. Horwitz EM, Prockop DJ, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 755–764.
25. Webster WS, Ahela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81: 215–228.
26. Webster WS, Ahela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81: 215–228.
27. Webster WS, Ahela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81: 215–228.
28. Webster WS, Ahela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81: 215–228.